InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026, tell me about this news today
02-10-2026
InflaRx announced today that it will present late-breaking pre-clinical data on izicopan (also known as INF904) at the American Society of Nephrology (ASN) Kidney Week 2026.
Key details highlighted in the announcement include:
Molecule & Mechanism: Izicopan is an orally administered, low-molecular-weight inhibitor targeting the complement C5a receptor (C5aR1). It is designed to block C5a-mediated inflammatory signaling while leaving membrane attack complex (C5b-9) formation intact.
Pre-clinical Findings: The late-breaking presentation focuses on izicopan’s efficacy in animal disease models of severe kidney disorders, specifically demonstrating significant reductions in renal inflammation, cellular infiltration, and organ tissue damage compared to control groups.
Clinical Significance: Complement activation through the C5a/C5aR1 pathway plays a major driver role in rare and acute kidney conditions like ANCA-associated vasculitis and other complement-mediated glomerulopathies. An oral agent offers a non-invasive, daily therapeutic alternative to current injectable anti-complement therapies.
Presentation Venue: The data will be shared during the late-breaking poster session at ASN Kidney Week 2026, marking a key milestone as InflaRx prepares to advance the compound into planned mid-stage clinical studies for renal indications.